Study guide

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols

Certified Addictions Registered Nurse - Advanced Practice CARN-AP

Track your progress as you read

Finished sections get a check mark.

1 Introduction: The CARN-AP Examination & Foundations of Advanced Addictions Practice

About the CARN-AP Examination: Blueprint, Scoring & Eligibility The Neurobiology of Addiction: Binge, Withdrawal & Preoccupation Screening, SBIRT & the ASAM Criteria Levels of Care

2 Chapter 1: Opioid Use Disorder: Assessment, Overdose Response & Methadone Maintenance

1.1 OUD Assessment, DSM-5-TR Diagnostic Criteria, and Clinical Opiate Withdrawal Scale (COWS) 1.2 Methadone Pharmacology, OTP Federal Regulations, QTc Prolongation & CYP450 Interactions 1.3 Opioid Overdose Assessment, Harm Reduction, Naloxone Formulations & Nalmefene

3 Chapter 2: Buprenorphine Protocols, Long-Acting Injectables & Naltrexone

2.1 Buprenorphine Pharmacology, Standard Office/Home Induction & Precipitated Withdrawal Management 2.2 Low-Dose Micro-Induction (Bernese Method) & Fentanyl Transition Strategies 2.3 Long-Acting Injectable Buprenorphine (Sublocade, Brixadi) & Extended-Release Naltrexone (Vivitrol)

4 Chapter 3: Alcohol Use Disorder: Neurobiology, Assessment & Acute Withdrawal

3.1 AUD Neurobiology, Epidemiology, Screening Instruments (AUDIT, AUDIT-C, CAGE) & Laboratory Biomarkers 3.2 Alcohol Withdrawal Syndrome, CIWA-Ar Protocol, Symptom-Triggered Benzodiazepine Regimens & Delirium Tremens 3.3 Wernicke-Korsakoff Syndrome, High-Dose Parenteral Thiamine Protocols & Acute Medical Complications

5 Chapter 4: Medications for Alcohol Use Disorder (MAUD)

4.1 Oral and Injectable Naltrexone for AUD: Mechanism, Prescribing Protocols & Clinical Efficacy 4.2 Acamprosate Calcium: NMDA Modulation, Renal Dosing Parameters & Abstinence Maintenance 4.3 Disulfiram and Second-Line / Off-Label MAUDs: Topiramate, Gabapentin & Baclofen

6 Chapter 5: Stimulant, Sedative-Hypnotic & Synthetic Substance Use Disorders

5.1 Stimulant Use Disorder (Cocaine & Methamphetamine): Neurotoxicity, Medical Emergencies & Evidence-Based Interventions 5.2 Sedative, Hypnotic, and Anxiolytic Disorders: Dependence Physiology, Risks & Outpatient Tapering Protocols 5.3 Emerging Synthetic Drugs: Fentanyl Analogues, Synthetic Cathinones, Cannabinoids & Xylazine-Associated Necrotic Wounds

7 Chapter 6: Tobacco and Cannabis Use Disorders: Evidence-Based Pharmacotherapy & Interventions

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols 6.2 Cannabis Use Disorder, Synthetic Cannabinoids & Cannabinoid Hyperemesis Syndrome 6.3 Behavioral Therapies in Substance Use: Motivational Interviewing, CBT & Contingency Management

8 Chapter 7: Psychiatric Differential Diagnosis & Medical Mimics in Addictions

7.1 Diagnostic Formulation: Primary vs. Substance-Induced Psychiatric Disorders & The 30-Day Rule 7.2 Endocrine, Neurological, and Metabolic Mimics of Substance Intoxication and Withdrawal 7.3 Decisional Capacity, Competency, and Involuntary Commitment in Acute Addiction Practice

9 Chapter 8: Co-Occurring Psychiatric Disorders: Integrated Treatment Planning

8.1 Integrated Dual Diagnosis Treatment (IDDT) Framework & High-Prevalence Mood / Anxiety Co-Occurring Disorders 8.2 Complex Severe Mental Illness: Psychotic Disorders, Bipolar Disorder & Borderline Personality in Addictions 8.3 Trauma-Informed Care, PTSD, and Addictions: Evidence-Based Integrated Psychotherapy

10 Chapter 9: Pain Management in Substance Use Disorders & CDC 2022 Guidelines

9.1 CDC 2022 Clinical Practice Guideline for Prescribing Opioids for Chronic Pain: Individualized Assessment vs. Hard Caps 9.2 Multimodal Non-Opioid Pharmacotherapy, Interventional Modalities & Non-Pharmacological Strategies 9.3 Acute Pain Management in Patients on Maintenance MOUD (Methadone, Buprenorphine, Naltrexone)

11 Chapter 10: Perinatal Substance Use, Neonatal Abstinence & Infectious Complications

10.1 Perinatal Substance Use Disorder: ACOG/ASAM Guidelines, MOTHER Trial & Maintenance MOUD 10.2 Neonatal Abstinence Syndrome (NAS/NOWS): Finnegan Scoring vs. Eat, Sleep, Console (ESC) & Breastfeeding 10.3 Infectious Complications in People Who Inject Drugs: Viral Hepatitis, HIV, Endocarditis & PrEP/PEP

12 Chapter 11: Federal Regulations, Confidentiality & Controlled Substance Prescribing

11.1 Controlled Substances Act, DEA Registration, Schedule Classifications & MAT Act of 2023 11.2 Confidentiality of Substance Use Disorder Patient Records: 42 CFR Part 2 (2024 Final Rule) & HIPAA Harmonization 11.3 Prescription Drug Monitoring Programs (PDMP) & Urine Drug Testing (UDT) Interpretation

13 Chapter 12: APRN Scope of Practice, Ethical Foundations, Harm Reduction & Research Literacy

12.1 APRN Scope of Practice, Prescriptive Authority & Collaborative Practice Regulations 12.2 Ethical Dilemmas in Addictions Nursing: Stigma, Autonomy, Justice, and Maternal/Fetal Rights 12.3 Harm Reduction Philosophy, Syringe Service Programs, Drug Checking & Overdose Prevention 12.4 Landmark Clinical Trials & Research Literacy in Addictions Medicine

14 Chapter 13: Stimulant Use Disorder in Depth — Methamphetamine, Withdrawal, Treatment & Harm Reduction

13.1 Methamphetamine Use Disorder: Pharmacology, Medical & Psychiatric Sequelae 13.2 Stimulant Withdrawal, Craving & Contingency Management 13.3 Pharmacotherapy Research for Stimulant Use Disorder 13.4 Stimulant Harm Reduction, Overamping & Patient Education

15 Chapter 14: Medical Consequences of Alcohol Use — Liver, Heart, Cancer & Nutrition

14.1 Alcohol-Associated Liver Disease: Staging, Scoring & Management 14.2 Cardiovascular, Oncologic & Nutritional Consequences of Alcohol

16 Chapter 15: Brief Intervention, Drinking Goals & Recovery Support in Alcohol Use Disorder

15.1 Brief Intervention, Drinking Goals & Shared Decision Making in AUD 15.2 Relapse Prevention, Mutual-Help Programs & Recovery Support

17 Chapter 16: Tobacco Use Disorder in Depth — Neurobiology, Assessment & Special Populations

16.1 Nicotine Neurobiology, Epidemiology & the Tobacco Product Landscape 16.2 Tobacco Assessment & Behavioral Treatment: 5 A's, Quitlines & Incentives 16.3 Tobacco Treatment in Special Populations & Co-Occurring Disorders

18 Chapter 17: Cannabis Use Disorder in Depth — Products, Treatment & Policy

17.1 Cannabinoid Pharmacology, Potency & the Modern Product Landscape 17.2 Cannabis Use Disorder: Epidemiology, Assessment & Treatment Evidence 17.3 Medical Cannabis, Legalization Policy, Adolescent Risk & Patient Education

19 Chapter 18: Other Use Disorders — Inhalants, Hallucinogens, Process Addictions & Prescription/OTC Misuse

18.1 Inhalant Use Disorder: Volatile Solvents, Nitrous Oxide & Alkyl Nitrites 18.2 Hallucinogens & Dissociatives: Classic Psychedelics, PCP, Ketamine & HPPD 18.3 Process (Behavioral) Addictions: Gambling Disorder, Gaming & Compulsive Behaviors 18.4 Prescription & Over-the-Counter Substance Misuse: Opioids, Stimulants, Kratom & DXM

20 Chapter 19: Educating Patients, Families & the Public (CARN-AP Activity Area III)

19.1 Designing Health Teaching: Literacy, Readiness, Culture & Teach-Back 19.2 Medication Education, Informed Consent & Informed Refusal 19.3 Family & Support-System Education: CRAFT, Al-Anon & Overdose Prevention Teaching 19.4 Public, Professional & Anticipatory Guidance: Prevention and Advocacy Teaching

21 Chapter 20: Consultation, Collaboration & Care Coordination (CARN-AP Activity Area IV)

20.1 The APRN Consultation Process & Communicating Recommendations 20.2 Interprofessional Collaboration, Care Coordination & Transitions of Care 20.3 Community Resources, Systems Navigation & Collaborative Documentation

22 Chapter 21: Quality Improvement, Evidence & Leadership in Addictions Nursing (CARN-AP Activity Area V)

21.1 Outcome Measurement & Continuous Quality Improvement in Addictions Care 21.2 Policy Advocacy, Leadership & the Determinants of Addiction

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols

Key Takeaways Explain This Topic AI

Nicotine binds stereoselectively to presynaptic alpha-4-beta-2 (α4β2) nicotinic acetylcholine receptors (nAChRs) in the ventral tegmental area (VTA), triggering burst dopamine release in the nucleus accumbens shell; rapid receptor desensitization drives compensatory receptor upregulation, producing intense craving and withdrawal within 1 to 2 hours of cessation.

The Fagerström Test for Nicotine Dependence (FTND) quantifies physiological physical dependence; 'time to first cigarette after waking' (≤5 minutes = high dependence, 3 points) is the single most predictive clinical indicator of relapse vulnerability and severe nocturnal withdrawal.

Combination / Dual Nicotine Replacement Therapy (NRT)—pairing a 24-hour transdermal patch (21 mg/day if >10 cigs/day; 14 mg/day if ≤10 cigs/day) for steady baseline plasma concentrations with a short-acting agent (gum, lozenge, nasal spray, inhaler) for acute breakthrough cravings—is dramatically superior to any NRT monotherapy.

Varenicline is an α4β2 nAChR partial agonist providing 40–60% low-level intrinsic dopamine tone to suppress withdrawal and cravings, while competitively antagonizing exogenous nicotine binding to blunt lapse reinforcement; standard titration is 0.5 mg daily (days 1–3), 0.5 mg BID (days 4–7), and 1.0 mg BID (day 8+), with the landmark EAGLES trial definitively establishing neuropsychiatric safety and removing the FDA boxed warning.

Bupropion SR is a dopamine/norepinephrine reuptake inhibitor (DNRI) and non-competitive nAChR antagonist dosed at 150 mg daily for 3 days then 150 mg BID; it has mandatory, non-negotiable contraindications including current or prior seizure disorders, current or prior anorexia nervosa or bulimia, abrupt withdrawal from alcohol or sedatives, and concurrent MAOI use.

Last updated: September 2026

6.1 Tobacco Use Disorder & Nicotine Dependence: Dual NRT, Varenicline & Bupropion Prescribing Protocols

Quick Answer: Inhaled nicotine binds stereoselectively to α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ nicotinic acetylcholine receptors (nAChRs) on dopaminergic neurons in the ventral tegmental area (VTA) , eliciting rapid burst firing and massive dopamine efflux in the nucleus accumbens (NAc) . Rapid receptor desensitization leads to a 300–400% compensatory upregulation of nAChR density, creating severe withdrawal symptoms (irritability, anxiety, restlessness, hedonic crash) within 60–120 minutes. Assessment relies on the Fagerström Test for Nicotine Dependence (FTND) , where time to first cigarette after waking ( ≤ 5 \le 5 ≤ 5 minutes = high dependence) is the single strongest predictor of physical dependence. First-line pharmacotherapies include Combination / Dual NRT (transdermal patch 21 mg/day for baseline kinetics plus rapid-acting 4 mg gum or lozenge for breakthrough cravings), Varenicline (0.5 mg daily → \to → 0.5 mg BID → \to → 1 mg BID; α4β2 partial agonist; proven neuropsychiatrically safe in the EAGLES trial ), and Bupropion SR (150 mg daily → \to → 150 mg BID; DNRI and nAChR antagonist). Bupropion is strictly contraindicated in patients with a history of seizures , anorexia or bulimia , abrupt alcohol/sedative withdrawal , or concurrent MAO inhibitor use.

1. Neurobiology of Nicotine Dependence & Receptor Kinetics

Tobacco Use Disorder (TUD) is among the most lethal and intractable substance use disorders encountered in clinical practice. The speed of delivery and complex allosteric receptor dynamics make nicotine uniquely habit-forming. Inhaled Nicotine (Puffs reach brain in 7–10 seconds)

  • │
  • ▼
  • Binds Presynaptic α4β2 nAChR Pentamers in VTA
  • │
  • ▼
  • Influx of Ca²⁺ & Na⁺ ──▶ Depolarization & Burst Firing
  • │
  • ▼
  • Dopamine Efflux into Nucleus Accumbens Shell (Reward & Salience)
  • │
  • ▼
  • Rapid Receptor Desensitization (Channels lock in closed state)
  • │
  • ▼
  • Receptor Resensitization (Arterial nicotine drops, t½ ~2 hours)
  • │
  • ▼
  • Compensatory Upregulation (300–400% receptor density increase)
  • │
  • ▼
  • Cholinergic Hypofunction & Locus Coeruleus Hyperarousal ──▶ Craving & Withdrawal
  • Molecular Receptor Kinetics: The α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ Pentamer

Nicotinic acetylcholine receptors (nAChRs) are pentameric ligand-gated ion channels composed of combinations of α \alpha α ( α 2 \alpha_2 α 2 ​ to α 10 \alpha_{10} α 10 ​ ) and β \beta β ( β 2 \beta_2 β 2 ​ to β 4 \beta_4 β 4 ​ ) subunits. The α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ heteropentamer represents the primary mediator of nicotine dependence in the central nervous system:

High-Affinity Agonism: Inhaled nicotine diffuses across alveolar capillaries into pulmonary venous circulation, entering cerebral circulation within 7 to 10 seconds —faster than intravenous administration. Nicotine binds with nanomolar affinity to the interfacial orthosteric binding pockets of α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ nAChRs located on cell bodies and presynaptic terminals of dopaminergic projection neurons within the ventral tegmental area (VTA) .

Burst Firing & Dopamine Efflux: Agonist binding produces conformational rotation of M2 transmembrane helices, opening a central cation-selective pore. The resulting rapid inward influx of calcium ( C a 2 + Ca^{2+} C a 2 + ) and sodium ( N a + Na^+ N a + ) depolarizes the membrane, switching dopaminergic neurons from tonic low-frequency pacemaking to high-frequency phasic burst firing . This generates massive dopamine efflux into the shell of the nucleus accumbens (NAc) and prefrontal cortex, reinforcing smoking behavior and encoding incentive salience.

Receptor Desensitization: Within seconds to minutes of continuous agonist exposure, α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ receptors transition into an inactive, non-conducting desensitized state . In this state, the channel pore remains closed despite bound ligand, rendering the neuron temporarily unresponsive to additional nicotine.

Compensatory Receptor Upregulation: The chronic cycle of repeated agonist binding followed by prolonged receptor desensitization paradoxically causes homeostatic upregulation of nAChR density by 300% to 400% across the human cerebral cortex and mesolimbic circuitry. The brain synthesizes and traffics an abnormally vast excess of α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ receptors to neuronal membranes to compensate for chronic desensitization.

Resensitization & The Withdrawal-Craving Cycle: As circulating arterial nicotine concentrations decline (elimination half-life of nicotine is approximately 2 hours ), the abundant upregulated receptors resensitize and revert to an unliganded resting state. Deprived of nicotine's stimulation, basal mesolimbic dopamine drops below baseline (reward deficit state), while excessive unliganded cholinergic receptors trigger widespread cholinergic hypofunction and disinhibit locus coeruleus noradrenergic hyperactivation . Within 60 to 120 minutes of the last cigarette, the patient experiences intense drug cravings, irritability, anxiety, autonomic tension, and difficulty concentrating.

2. Clinical Assessment & The Fagerström Test for Nicotine Dependence (FTND)

Accurate assessment of physical dependence guides the selection and intensity of pharmacotherapy. While DSM-5-TR establishes the diagnostic threshold for Tobacco Use Disorder (meeting ≥ 2 \ge 2 ≥ 2 of 11 behavioral and physiological criteria over 12 months), the Fagerström Test for Nicotine Dependence (FTND) is the gold-standard instrument for quantifying physical dependence severity.

The Fagerström Test for Nicotine Dependence (FTND)

Item Response Options Score

1. How soon after you wake up do you smoke your first cigarette? Within 5 minutes ; 6–30 minutes; 31–60 minutes; After 60 minutes 3 points ; 2 points; 1 point; 0 points

  • 2. Do you find it difficult to refrain from smoking in forbidden places? Yes; No 1 point; 0 points
  • 3. Which cigarette would you hate most to give up? The first one in the morning ; Any other 1 point ; 0 points

4. How many cigarettes per day do you smoke? 10 or less; 11–20; 21–30; 31 or more 0 points; 1 point; 2 points; 3 points

5. Do you smoke more frequently during the first hours after waking than during the rest of the day? Yes; No 1 point; 0 points

6. Do you smoke if you are so ill that you are in bed most of the day? Yes; No 1 point; 0 points

Important

Clinical Interpretation & Stratification:

  • Total Score 0–2: Very low dependence
  • Total Score 3–4: Low dependence
  • Total Score 5: Medium dependence
  • Total Score 6–7: High dependence
  • Total Score 8–10: Very high dependence

The Pathognomonic First Morning Cigarette: Item 1 ( Time to first cigarette after waking ) is the single most predictive question on the instrument. A patient who reaches for a cigarette within ≤ 5 \le 5 ≤ 5 minutes of waking has severe nocturnal nicotine clearance and overwhelming receptor resensitization, identifying profound physical dependence and an elevated risk of early relapse. These individuals require aggressive, high-dose combination pharmacotherapy.

Objective Laboratory Biomarkers

Exhaled Carbon Monoxide (CO): Carbon monoxide binds to hemoglobin with an affinity 200–250 times greater than oxygen, producing carboxyhemoglobin ( C O H b COHb CO H b ). Exhaled CO measured via handheld electrochemical breath analysis reflects combustible tobacco exposure within the prior 4 to 6 hours (half-life of exhaled CO is 2–8 hours, prolonged during sleep). A cutoff of > 6 to 8 parts per million (ppm) >6\text{ to }8\text{ parts per million (ppm)} > 6 to 8 parts per million (ppm) distinguishes active smokers from non-smokers.

Cotinine: Cotinine is the primary proximate proximate metabolite of nicotine, generated via hepatic CYP2A6 oxidation. Cotinine has an elimination half-life of 16 to 20 hours (compared to nicotine's 2 hours), making it an exceptionally reliable biomarker for validating abstinence over the prior 2 to 4 days:

Serum / Saliva: Non-smokers < 1 – 10 ng/mL <1\text{–}10\text{ ng/mL} < 1 – 10 ng/mL ; active combustible smokers typically > 100 – 500 ng/mL >100\text{–}500\text{ ng/mL} > 100 – 500 ng/mL .

Urine: Quantitative cutoff ≥ 50 – 200 ng/mL \ge 50\text{–}200\text{ ng/mL} ≥ 50 – 200 ng/mL confirms active tobacco or nicotine use. Cotinine does not distinguish combustible tobacco from NRT or electronic nicotine delivery systems (ENDS).

3. First-Line Pharmacotherapies: Dual/Combination NRT Prescribing Protocols

Clinical guidelines from the American Thoracic Society (ATS) and the US Public Health Service (USPHS) establish that Combination / Dual NRT is dramatically superior to monotherapy (odds ratio ~1.35 to 1.55 versus patch monotherapy; OR ~2.0 versus placebo). Monotherapy frequently fails because a single modality cannot replicate the dual kinetics of combustible cigarettes: a continuous baseline plateau plus rapid spikes in response to environmental triggers. [Combination / Dual NRT Regimen]

  • ├── 1. Long-Acting Transdermal Patch ──▶ Sustained, zero-order baseline plasma levels
  • │ (Prevents baseline withdrawal and physical cravings)
  • └── 2. Short-Acting Breakthrough Agent ──▶ Rapid buccal/nasal spikes on-demand
  • (Gum, Lozenge, Inhaler, Spray) (Suppresses acute cue-induced craving surges)
  • Transdermal Nicotine Patch: Baseline Kinetics & Dosing

The transdermal patch delivers nicotine across the stratum corneum via slow zero-order diffusion, achieving steady plasma concentrations over 24 hours. Peak plasma levels are reached 4 to 9 hours post-application.

Heavy Smokers ( > 10 >10 > 10 cigarettes/day [half-pack or more], or FTND ≥ 6 \ge 6 ≥ 6 ):

  • Step 1: 21 mg/24 hours 21\text{ mg/24 hours} 21 mg/24 hours daily for 4 to 6 weeks
  • Step 2: 14 mg/24 hours 14\text{ mg/24 hours} 14 mg/24 hours daily for 2 weeks
  • Step 3: 7 mg/24 hours 7\text{ mg/24 hours} 7 mg/24 hours daily for 2 weeks

Light Smokers ( ≤ 10 \le 10 ≤ 10 cigarettes/day, or body weight < 45 kg <45\text{ kg} < 45 kg ):

  • Step 2: 14 mg/24 hours 14\text{ mg/24 hours} 14 mg/24 hours daily for 6 weeks
  • Step 3: 7 mg/24 hours 7\text{ mg/24 hours} 7 mg/24 hours daily for 2 weeks

Application Instructions & APRN Counseling:

Apply once daily every morning to clean, dry, hairless skin of the upper outer arm, chest, or upper back. Rotate anatomical sites daily to avoid contact dermatitis.

Sleep Disturbances & Vivid Dreams: If the patient experiences nocturnal insomnia or vivid/nightmarish dreams, the patch may be removed at bedtime (creating a 16-hour wear schedule ), though morning withdrawal upon waking will be higher.

Short-Acting Breakthrough Formulations

Short-acting NRT formulations are titrated on-demand to neutralize breakthrough cravings triggered by classical conditioning (e.g., driving, post-meal, social cues):

Nicotine Polacrilex Gum: Available in 2 mg 2\text{ mg} 2 mg and 4 mg 4\text{ mg} 4 mg formulations.

Dosing Rule: If the patient smokes their first cigarette ≤ 30 \le 30 ≤ 30 minutes of waking , use the 4 mg 4\text{ mg} 4 mg strength; if > 30 >30 > 30 minutes, use the 2 mg 2\text{ mg} 2 mg strength. Minimum 9 pieces/day for first 6 weeks (maximum 24 pieces/day).

Administration Technique ("Chew and Park"): Chew slowly until a peppery taste or tingling sensation emerges (~15 chews); immediately "park" the gum between the buccal mucosa and gum tissue to allow passive transmucosal absorption. When tingling subsides, chew again and re-park on the opposite side. Discard after 30 minutes. Common Error: Chewing continuously like confectionary gum causes swallowing of nicotine, producing severe dyspepsia, hiccups, nausea, and blunted systemic absorption.

Acidic Beverage Restriction: Patients must avoid acidic beverages (coffee, tea, soda, citrus juices, wine) for 15 minutes before and during gum or lozenge use. Acidic pH protonates nicotine, creating an ionized form that cannot cross the lipophilic buccal epithelium.

Nicotine Lozenge: Available in 2 mg 2\text{ mg} 2 mg and 4 mg 4\text{ mg} 4 mg strengths (utilizing the same 30-minute waking rule). Allowed to dissolve slowly in the mouth over 20 to 30 minutes without chewing or swallowing. Delivers ~25% more nicotine than equivalent gum doses.

Nicotine Nasal Spray: 10 mg/mL 10\text{ mg/mL} 10 mg/mL solution delivering 0.5 mg 0.5\text{ mg} 0.5 mg per spray ( 1 spray 1\text{ spray} 1 spray in each nostril = 1 mg = 1\text{ mg} = 1 mg dose). Offers the fastest pharmacokinetic absorption of any NRT (peak plasma levels achieved in 5–10 minutes), closely mimicking the rapid onset of a cigarette. Initial dosage is 1–2 doses/hour (minimum 8 doses/day, max 40 doses/day). Frequent initial adverse effects include severe nasal burning, sneezing, and lacrimation (tachyphylaxis occurs within 48–72 hours). Relative contraindication in severe reactive airway disease or chronic nasal pathology.

Nicotine Oral Inhaler: Consists of a mouthpiece and plastic cartridge delivering 4 mg 4\text{ mg} 4 mg of vapor ( 2 mg 2\text{ mg} 2 mg absorbed across the buccal mucosa, not pulmonary alveoli). Uniquely addresses the behavioral and sensory hand-to-mouth ritual of smoking. Best used with frequent shallow puffing (80 deep puffs per cartridge over 20 minutes; 6–16 cartridges/day).

Overview of First-Line NRT Prescribing Protocols

Formulation Standard Dosing Peak Onset ( T max T_{\text{max}} T max ​ ) Mechanism / Route Clinical Pearls & Instructions

Transdermal Patch 21 mg/d ( ≥ 10 \ge 10 ≥ 10 cigs); 14 mg/d ( ≤ 10 \le 10 ≤ 10 cigs) 4–9 hours Continuous transdermal diffusion Rotate sites daily; remove at night (16-hr wear) if vivid dreams or insomnia occur.

Nicotine Gum 4 mg if TTFC ≤ 30 \le 30 ≤ 30 min;; 2 mg if TTFC > 30 >30 > 30 min 20–30 min Transmucosal buccal absorption "Chew and park" technique; no acidic drinks 15 min prior/during; max 24 pieces/day.

Nicotine Lozenge 4 mg if TTFC ≤ 30 \le 30 ≤ 30 min;; 2 mg if TTFC > 30 >30 > 30 min 20–30 min Transmucosal buccal absorption Dissolve slowly; do not chew or swallow; delivers 25% higher dose than gum.

Nasal Spray 1–2 mg/hr (1 spray each nostril); max 40 mg/d 5–10 min Nasal mucosa absorption Fastest NRT onset; high local irritation (burning, sneezing); avoid in severe asthma.

Oral Inhaler 6–16 cartridges/day (4 mg vapor/cartridge) 15–20 min Transmucosal buccal absorption Replaces behavioral hand-to-mouth habit; shallow puffing technique over 20 minutes.

4. Varenicline (Chantix): Pharmacology, Titration & The EAGLES Trial

Varenicline tartrate is a synthetic small molecule derived from the plant alkaloid cytisine, representing the most effective single-agent pharmacotherapy for tobacco cessation.

Mechanism of Action

Varenicline is a selective, high-affinity partial agonist at α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ neuronal nicotinic acetylcholine receptors :

Agonist Properties (Low-Level Intrinsic Efficacy): Varenicline exhibits approximately 40% to 60% of the maximal dopamine-releasing capacity of full agonist nicotine. By sustaining modest, basal dopaminergic tone in the nucleus accumbens, varenicline substantially alleviates the dysphoria, craving, and autonomic distress of acute nicotine withdrawal.

Antagonist Properties (Competitive Blunting): Because varenicline binds to the α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ receptor with significantly higher affinity than nicotine itself, it competitively occupies and blocks the binding site. If a patient slips and smokes a combustible cigarette while taking varenicline, nicotine is prevented from binding to the receptor. The patient experiences no dopaminergic surge or hedonic reinforcement, extinguishing the conditioned reward response. [Varenicline at α4β2 nAChRs]

  • │
  • ├─▶ Partial Agonism (40–60% baseline dopamine) ──▶ Alleviates Withdrawal & Cravings
  • │
  • └─▶ Competitive Blockade (Prevents Nicotine Binding) ──▶ Blunts Hedonic Reward upon Lapse
  • Clinical Prescribing & Titration Protocol

To minimize adverse gastrointestinal effects, varenicline must be incrementally titrated over one week before reaching the therapeutic target dose:

  • Days 1 to 3: 0.5 mg 0.5\text{ mg} 0.5 mg PO once daily in the morning
  • Days 4 to 7: 0.5 mg 0.5\text{ mg} 0.5 mg PO twice daily (morning and evening)
  • Day 8 through Week 12 (Target Quit Date Window): 1.0 mg 1.0\text{ mg} 1.0 mg PO twice daily

Target Quit Date Timing: The patient is advised to set a target quit date between Day 8 and Day 14 (1 to 2 weeks after initiating therapy), allowing the drug to reach steady-state plasma concentrations. Alternatively, a flexible quit approach allows quitting between days 8 and 35, or a gradual reduction approach over 12 weeks.

Duration of Therapy: Standard duration is 12 weeks . In patients who successfully achieve complete abstinence at 12 weeks, an additional 12 weeks of maintenance therapy (total 24 weeks) is strongly recommended to consolidate abstinence and prevent delayed relapse.

Renal Impairment Dosing: Varenicline undergoes minimal hepatic metabolism and is primarily eliminated unchanged by the kidneys ( > 90 % >90\% > 90% ). For patients with severe renal impairment (Creatinine Clearance < 30 mL/min <30\text{ mL/min} < 30 mL/min ), the initial dose is 0.5 mg 0.5\text{ mg} 0.5 mg once daily, titrated to a maximum of 0.5 mg 0.5\text{ mg} 0.5 mg twice daily.

Adverse Effects & Mitigation Strategies

Nausea: Occurs in up to 30% of patients. It is dose-dependent and typically transient. Mitigation: Counsel patients to ingest varenicline with a full meal and a large glass of water (8 oz) . If persistent, down-titrate to 0.5 mg 0.5\text{ mg} 0.5 mg BID.

Neuropsychiatric / Sleep Disturbances: Vivid, abnormal, or bizarre dreams and insomnia occur in 10–15% of patients. Mitigation: Shift the second daily dose from bedtime to dinner time (early evening, 5–6 PM) to reduce nocturnal peak cerebral drug concentrations.

The Landmark EAGLES Trial

Historically, post-marketing reports prompted the FDA to place a black box warning on varenicline and bupropion in 2009 regarding potential risks of severe neuropsychiatric symptoms (suicidality, depression, psychosis). To definitively assess this risk, the FDA mandated the EAGLES Trial ( Evaluating Adverse Events in a Global Smoking Cessation Study , published in The Lancet , 2016):

Design: A rigorous, double-blind, randomized, triple-dummy, active- and placebo-controlled trial across 16 countries, enrolling 8,144 adult smokers stratified into two distinct cohorts: a psychiatric cohort ( n = 4 , 116 n=4,116 n = 4 , 116 , with stable major depression, bipolar disorder, anxiety disorders, or schizophrenia) and a non-psychiatric cohort ( n = 4 , 028 n=4,028 n = 4 , 028 ). Participants received varenicline 1 mg BID, bupropion SR 150 mg BID, nicotine transdermal patch 21 mg/d, or placebo for 12 weeks.

Safety Findings: In both the psychiatric and non-psychiatric cohorts, there was no significant increase in serious neuropsychiatric adverse events (clinically significant suicidal ideation/behavior, aggression, psychosis, or panic) with varenicline or bupropion compared to nicotine patch or placebo.

Efficacy Findings: Varenicline demonstrated superior continuous abstinence rates compared to bupropion (odds ratio ~1.4), nicotine patch (OR ~1.3), and placebo (OR ~3.6) at weeks 9–12 and weeks 9–24.

Regulatory Outcome: Based on the conclusive EAGLES data, the FDA officially removed the black box warning from varenicline and bupropion in December 2016, establishing varenicline as a safe, first-line agent in patients with co-occurring psychiatric disorders.

5. Bupropion SR (Zyban): Mechanism, Dosing & Mandatory Contraindications

Bupropion sustained-release (SR) is an effective non-nicotine oral pharmacotherapy initially formulated as an antidepressant.

Neuropharmacology

Dopamine and Norepinephrine Reuptake Inhibition (DNRI): Bupropion and its active hepatic metabolites (hydroxybupropion) inhibit the dopamine active transporter (DAT) and norepinephrine transporter (NET) in the prefrontal cortex and nucleus accumbens. By increasing synaptic dopamine concentrations, bupropion attenuates the profound anhedonia and dysphoria of acute nicotine withdrawal.

Non-Competitive nAChR Antagonism: Bupropion acts as a functional, non-competitive antagonist at multiple nicotinic receptor subtypes, including α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ and α 3 β 4 \alpha_3\beta_4 α 3 ​ β 4 ​ . This antagonism blocks nicotine-mediated excitation.

Weight Attenuation: Bupropion uniquely delays or blunts post-cessation weight gain during active therapy, making it especially appealing for patients with body image concerns.

  • Dosing Protocol
  • Days 1 to 3: 150 mg 150\text{ mg} 150 mg PO once daily in the morning
  • Day 4 through Week 7–12: 150 mg 150\text{ mg} 150 mg PO twice daily

Spacing Requirement: Doses must be administered at least 8 hours apart to prevent high peak drug concentrations that reduce the seizure threshold. The second dose should be taken in the late afternoon (e.g., 4–5 PM) to minimize severe insomnia.

Target Quit Date: Set for 1 to 2 weeks after starting bupropion, ensuring therapeutic steady-state concentrations prior to tobacco discontinuation.

Mandatory Clinical Contraindications

Bupropion reduces the electroencephalographic seizure threshold in a dose-dependent manner (seizure incidence is approximately 0.1% at doses ≤ 300 mg/day \le 300\text{ mg/day} ≤ 300 mg/day , escalating tenfold at > 450 mg/day >450\text{ mg/day} > 450 mg/day ). The APRN must master the following absolute contraindications : [MANDATORY CONTRAINDICATIONS FOR BUPROPION]

  • ├── 1. Current or Prior Seizure Disorder (Epilepsy, febrile seizures)
  • ├── 2. Current or Past Diagnosis of Anorexia Nervosa or Bulimia Nervosa
  • ├── 3. Abrupt Discontinuation of Alcohol, Benzodiazepines, Barbiturates, or Antiepileptics
  • ├── 4. Concurrent Administration of MAOIs (or within 14 days of stopping MAOI)
  • └── 5. Severe Pre-existing Head Trauma or Active Central Nervous System Neoplasm

Current or Prior Seizure Disorder: Any personal history of unprovoked seizures or epilepsy absolutely precludes bupropion prescribing.

Current or Past Diagnosis of Bulimia Nervosa or Anorexia Nervosa: In pre-marketing trials, patients with active or historical purging behaviors experienced an unacceptably high rate of grand mal seizures (approximately 4%) due to transient electrolyte disturbances, fluid shifts, and metabolic dysregulation.

Abrupt Discontinuation of Alcohol, Sedatives, or Antiepileptics: Discontinuation of GABAergic modulators dramatically lowers the seizure threshold; concurrent bupropion creates a catastrophic seizure risk.

Concurrent Monoamine Oxidase Inhibitor (MAOI) Use: Administration within 14 days of an MAOI can precipitate a life-threatening hypertensive crisis.

6. Comparative Synthesis of First-Line Prescribing Options

Pharmacotherapy Primary Mechanism Standard Titration & Target Quit Date Proven Abstinence (OR vs Placebo) Key Adverse Effects Mandatory Contraindications & Warnings

Combination NRT (Patch + Gum/Lozenge) Full agonist at peripheral & central nAChRs; zero-order baseline + on-demand spikes Patch: 21 mg/d ( ≥ 10 \ge 10 ≥ 10 cigs); Gum/Lozenge: 4 mg on demand. Quit on Day 1 . OR ~2.0–2.3 Skin irritation, vivid dreams (patch); mouth soreness, dyspepsia (gum). Unstable angina, acute MI < 2 <2 < 2 weeks, severe refractory ventricular arrhythmias.

Varenicline (Chantix) High-affinity partial agonist at α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ nAChR; low dopamine tone + competitive block 0.5 mg daily d1–3 → \to → 0.5 mg BID d4–7 → \to → 1 mg BID d8+. Quit Days 8–14 . OR ~2.5–3.2 Nausea (take with food/water), insomnia, vivid dreams. Severe hypersensitivity, angioedema. Dose-reduce to 0.5 mg BID if CrCl < 30 <30 < 30 mL/min.

Bupropion SR (Zyban) DNRI + non-competitive antagonist at α 4 β 2 \alpha_4\beta_2 α 4 ​ β 2 ​ nAChRs; reduces withdrawal & weight 150 mg daily d1–3 → \to → 150 mg BID d4+. Doses ≥ 8 \ge 8 ≥ 8 hrs apart. Quit Days 7–14 . OR ~1.6–1.9 Insomnia, dry mouth, headache, agitation, tremor. Seizure history, anorexia/bulimia, abrupt alcohol/sedative withdrawal, concurrent MAOIs.